Burning Rock Dx

Thank you for attending the 3rd Annual Liquid Biopsy Surveillance Summit in Boston! Here are some of our highlights from the meeting. ?? Exciting insights from Xinru Mao, VP of Pharmaceutical Biomarker & CDx Services, presented on ctDNA Detection and Intervention, Challenges and Opportunities, exploring current practices and future prospects in ctDNA detection. ?? Engaging discussions on MRD detection in clinical trials, focusing on leveraging MRD-based approaches to optimize therapeutic interventions. Proud to be part of the conversation shaping the future of liquid biopsy. Stay tuned for more updates and follow us for more cutting-edge insights! #oncology #oncologyresearch #PrecisionOncology #MRD #residualdisease #clinicaltrials #biomarkers #liquidbiopsy #ctDNA #BurningRockDx

Established in 2014, Burning Rock focuses on precision oncology, committed to developing innovative, reliable, and clinically valuable products for cancer detection and therapy. In 2018, we achieved a significant milestone by receiving the first approval for a tumor NGS kit from China’s National Medical Products Administration (NMPA). With certifications such as CLIA, CAP, and ISO 15189, we continue to advance cutting-edge technologies in oncology. Explore our experience, knowledge, and commitment to influencing precision medicine's future in our corporate video. #BurningRockDx #oncology #NGS #NextGenerationSequencing #CDx #PrecisionMedicine #GeneticTesting

?????????????? ???????? ???? ???????? ???? ?????????????????????????? ???? ?????? ?????? ???????????? ???????????? ???????????? ???????????????????????? ???????????? ???? ???????????? ???? ???????????????? ????-????! This key event will bring together top experts and industry leaders to explore the latest breakthroughs in liquid biopsy technologies, with a focus on advancing cancer detection, monitoring, and treatment. Join us for a special presentation by xinru mao, Vice President of Pharmaceutical Biomarker & CDx Services at Burning Rock Dx, on November 21st at 12:30 PM. We will discuss the latest developments in ctDNA Detection and Intervention, addressing both the challenges and opportunities in this rapidly evolving field. Key topics to be covered include: - Current practices and future prospects in ctDNA detection. - The evolving role of liquid biopsy in cancer therapy. - Leveraging MRD-based approaches to optimize therapeutic intervention. If you're attending and would like to meet us, come by and say hello at our booth, No. 5, in the exhibition area! ??? #oncology #oncologyresearch #PrecisionOncology #MRD #residualdisease #clinicaltrials #biomarkers #liquidbiopsy #ctDNA #BurningRockDx

?? Burning Rock Dx and MGI Tech Announce Strategic Partnership to Advance Precision Oncology ?? This collaboration leverages MGI Tech's cutting-edge DNBSEQ sequencing technology to jointly drive innovation and development in the field of precision oncology. The partnership aims to accelerate the clinical application of precise cancer diagnostics and therapies, while advancing the companies' global business expansion. The signing ceremony was attended by Han Yusheng, Founder & CEO of Burning Rock Dx, and Mu Feng, CEO of MGI Tech, both of whom expressed great anticipation for the future of this collaboration. The two companies will combine their technological strengths to accelerate the registration and approval of cancer-related products, foster breakthroughs in diagnostic and therapeutic technologies, and promote the global adoption of these innovations. #DNBSEQ #PrecisionOncology #Sequencing #Genomics #Biotech #CancerCare #PersonalizedMedicine #BurningRockDx

?????????????? ???????? ???? ???????????????????????? ?????????? ?????? ???????????? ?????????????????? ???????????????? ???????????? We recently held the fourth Precision Medicine Summit, attracting over 150 guests from multinational companies, large pharmaceutical firms, and biotechnology enterprises. The summit featured three specialized roundtable discussions and over ten keynote presentations, covering critical topics such as the development of translational medicine, challenges of companion diagnostics in global markets, and laboratory operational standards. With standardized operations across our laboratories in both the U.S. and China, we are dedicated to empowering companies in their global expansion efforts and advancing precision oncology worldwide. Together, we aim to protect and enhance the lives of cancer patients globally. Thank you to all participants for making this summit a success! ??? #Diagnostics #PrecisionMedicine #MNC #Pharma #Biotech #CancerDiagnostics #Genomics #NextGenDx #NGS #BurningRockDx

?? Burning Rock Dx Spotlight: LungCure CDx ?? Burning Rock LungCure CDx, a pioneering NMPA-approved NGS-based companion diagnostic kit designed to transform lung cancer treatment. By covering 9 critical lung cancer-associated genes, LungCure CDx empowers clinicians to make informed therapy selections tailored to individual patient profiles. ?? Key Features:? ?? Clinically Validated with Rare Variant Detection:? Lungcure CDx has proven reliability with over 2,000 clinical samples, excelling in the detection of rare variants. ?? Broad NSCLC Mutation Coverage: As China’s first NGS kit approved for MET exon 14 skipping and MET amplification detection, Lungcure CDx spans EGFR, MET, ERBB2, KRAS, BRAF, PIK3CA, ALK, ROS1, and RET mutations, offering complete guidance for NSCLC therapies. ?? Strategic Pharma Partnerships: In collaboration with top global and domestic pharma companies, Lungcure CDx is advancing precision oncology and setting new standards for targeted cancer care. For additional information, please visit us at us.brbiotech.com. #Diagnostics #PrecisionMedicin #PrecisionOncology #lungcancer #cancer #CancerDiagnostics #NextGenDx #NGS #BurningRockDx

?? November is Lung Cancer Awareness Month. This month, we emphasize the importance of comprehensive biomarker testing for lung cancer patients, which is essential for matching the right treatments to individual needs. ?? Our clinically proven NGS-based assays empower clinicians and patients with actionable insights that enhance treatment decisions. Join us in raising awareness and supporting patients in their journey to recovery. #lungcancerawarenessmonth #lungcancer #precisionmedicine #oncology #BurningRockDx

???????????????????????????? ?????? ???????? ???????????? ????????????????! The co-development of Burning Rock's LungCure CDx kit and Dizal's innovative treatment, Sunvozertinib, providing a novel solution for patients with EGFR exon20ins insertion mutations. ?? Approved by NMPA, this CDx test is a key tool in tailoring personalized therapies.? ?? Innovative Targeted Therapy: Sunvozertinib stands out as a breakthrough EGFR inhibitor, demonstrating significant efficacy even in patients with pretreated brain metastases. ?? Comprehensive Solution: The LungCure CDx tests for multiple gene mutations (EGFR, MET, ALK, and more), offering an all-in-one diagnostic for NSCLC patients. This groundbreaking collaboration ultimately benefits patients by providing them with more effective, personalized treatment options. We are bringing new hope to patients! ??? Read more:https://lnkd.in/gqvEK-sg #BurningRockDx #CompanionDiagnostic #NGS #NextGenDx #LungCancer #Cancer #TargetedTherapy #CDx #precisionmedicine

Burning Rock Dx latest original collaborative achievements! ?? Key Points?? 1?? Differential Treatment of Pathological Subtypes in Biomarker Research: The predictive effects of LRP1B mutations differ between sqNSCLC and nsqNSCLC subtypes. 2?? Higher Frequency of Non-Synonymous Mutations in Longer Genes: Longer genes exhibit a higher frequency of non-synonymous mutations, which can interfere with predictive effects. 3?? LRP1B Gene Testing is valuable for NSCLC Immunotherapy: OncoCompass?Plus-520 gene panel includes the full-length LRP1B gene, enabling comprehensive detection of all LRP1B mutations and assisting in the identification of NSCLC patients suitable for immunotherapy. Read the complete study here: https://lnkd.in/ecUN3tWa #Oncology #BurningRockDx #biomarker #precisionmedicine #immunotherapy #healthcare?#NSCLC

?????October is Breast Cancer Awareness Month. Let’s unite to raise awareness and support those affected by breast cancer. Early detection is crucial—schedule your screenings and encourage your loved ones to do the same. Together, we can make a difference! #BurningRockDx #BreastCancer #BreastCancerAwareness #BreastCancerAwarenessMonth #CDx #NGS